Horizon and ATUM combine tech to offer stable cell line production
Horizon Discovery will add vector and transposase technology to its gene editing services through a cross-licensing partnership with gene and protein expression services firm ATUM.
Archives for June 1, 2017
Patheon to manufacture amyloidosis antibody treatment for Caelum
Caelum Biosciences has selected Patheon to make its lead antibody CAEL-101 to treat orphan disease amyloid light-chain (AL) amyloidosis.